The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - GenoScience Pharma; Neuronax; SCOR
Honoraria - GenoScience Pharma; PharmaEngine; SCOR
Consulting or Advisory Role - AFR-Oncology
SPRING: A Worldwide Innovative Network (WIN) Consortium phase I study of triple therapy (avelumab, axitinib, and palbociclib) in advanced non-small cell lung cancer (NSCLC) with genomic and transcriptomic correlates.
 
Benjamin Maurice Solomon
Travel, Accommodations, Expenses - AstraZeneca/MedImmune
 
Ana Callejo
Consulting or Advisory Role - Boehringer Ingelheim; Kyowa Hakko Kirin; Lilly; MSD Oncology; Roche Pharma AG; Sanofi
Travel, Accommodations, Expenses - Boehringer Ingelheim; Celgene; Kyowa Hakko Kirin; MSD Oncology; Pfizer; Roche Pharma AG
 
Jair Bar
Honoraria - Roche
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Pfizer; Roche/Genentech; Takeda
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Guy J. Berchem
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Roche
 
Lyudmila Bazhenova
Stock and Other Ownership Interests - Epic Sciences
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeyondSpring Pharmaceuticals; Blueprint Medicines; Boehringer Ingelheim; G1 Therapeutics; Genentech/Roche; Loxo; Novartis; Takeda
Research Funding - BeyondSpring Pharmaceuticals
 
Pierre Saintigny
Honoraria - Archer; Bristol-Myers Squibb; HTG Molecular Diagnostics; Inivata; Roche Molecular Diagnostics
Research Funding - AstraZeneca; Bristol-Myers Squibb; Novartis; Roche
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Illumina; Roche
 
Eric Raymond
No Relationships to Disclose
 
Nicolas Girard
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; MSD; Novartis; Pfizer; Pharmamar; Roche; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology; Roche
 
Raed Sulaiman
No Relationships to Disclose
 
Bruce Prouse
No Relationships to Disclose
 
Catherine Bresson
Research Funding - Lilly (Inst)
Patents, Royalties, Other Intellectual Property - WIN Association (Inst)
 
Fanny Wunder
Research Funding - Lilly (Inst)
Patents, Royalties, Other Intellectual Property - WIN Association (Inst)
 
J. Jack Lee
Consulting or Advisory Role - Abbvie
 
Jacques Raynaud
No Relationships to Disclose
 
Eitan Rubin
No Relationships to Disclose
 
Vladimir Lazar
Research Funding - Lilly (Inst)
Patents, Royalties, Other Intellectual Property - WIN Association (Inst)
 
Enriqueta Felip
Consulting or Advisory Role - Abbvie; AstraZeneca; BerGenBio; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Janssen; Lilly; Medscape; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; priME Oncology; Roche; Samsung; Takeda; touchIME
Speakers' Bureau - Abbvie; AbbVie; AstraZeneca; BerGenBio; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Janssen; Lilly; medscape; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; Prime Oncology; Roche; Samsung; Takeda; touchIME
Research Funding - EMD Serono (Inst); Merck (Inst)
Other Relationship - GRÍFOLS
 
Amir Onn
Honoraria - Boehringer Ingelheim; MSD; Roche
Consulting or Advisory Role - Boehringer Ingelheim
Speakers' Bureau - AstraZeneca
 
Brian Leyland-Jones
Leadership - NED Biosystems
Stock and Other Ownership Interests - ARIAD; Catalyst Pharmaceuticals; Progenix; Puma Biotechnology; Sucampo Pharmaceuticals; Zogenix
Consulting or Advisory Role - Amgen; GlaxoSmithKline
Speakers' Bureau - Bayer; Exelixis; Genentech; Puma Biotechnology
Research Funding - Takeda; Tesaro
Expert Testimony - Amgen
Travel, Accommodations, Expenses - AKESOgen; National Foundation for Cancer Research
Other Relationship - AKesoGen
 
Razelle Kurzrock
Leadership - CureMatch; CureMetrix
Stock and Other Ownership Interests - CureMatch; IDbyDNA; Soluventis
Honoraria - AACR; Advanced Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; LEK; NeoGenomics Laboratories; NeoMed; Roche; Wiley
Consulting or Advisory Role - Actuate Therapeutics; Gaido; Loxo; Merck; NeoMed; Pfizer; Roche; Soluventis; XBiotech
Speakers' Bureau - Roche
Research Funding - Boehringer Ingelheim (Inst); Debiopharm Group (Inst); Foundation Medicine (Inst); Genentech (Inst); Grifols (Inst); Guardant Health (Inst); Incyte (Inst); Konica Minolta (Inst); Merck Serono (Inst); OmniSeq (Inst); Pfizer (Inst); Sequenom (Inst)
Travel, Accommodations, Expenses - AACR; Advanced Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; LEK; NeoGenomics Laboratories; NeoMed; Roche; Wiley